HIGHLIGHTS
- who: Yi-Li Chen from the Yi-Li Chen1, , *, Yue Cui3, Xinyuan Liu2, Guojian Liu3, Xingchen Dong3, Lei Tang2, Yifeng Hung2, Chunhe Wang2, , *, and Mei-Qing Feng1, * From the Department of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China have published the research: A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy, in the Journal: (JOURNAL) of July/22,/2021
- what: The authors propose that the enhanced antitumor activities of BsAb in_vivo may be due to direct inhibition of HER2 signaling or . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.